Structural basis for the specificity of renin-mediated angiotensinogen cleavage. by Yan, Yahui et al.
Specificity of angiotensinogen cleavage by renin 
 1 
Structural basis for the specificity of renin-mediated angiotensinogen 
cleavage 
Yahui Yan1 (严亚慧), Aiwu Zhou2*(周爱武), Robin W. Carrell1, Randy J. Read1* 
From the 1Department of Haematology, University of Cambridge, Cambridge Institute for Medical 
Research, Wellcome Trust/MRC Building, Hills Road, Cambridge CB2 0XY, U.K.; 2Hongqiao 
International Institute of Medicine, Shanghai Tongren Hospital/Faculty of Basic Medicine, Key 
Laboratory of Cell Differentiation and Apoptosis of the Chinese Ministry of Education, Shanghai Jiao-
Tong University School of Medicine, China 
Running title: Specificity of angiotensinogen cleavage by renin 
*To whom correspondence should be addressed: Randy J. Read: Department of Haematology, University 
of Cambridge, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Hills Road, 
Cambridge CB2 0XY, U.K.; rjr27@cam.ac.uk; Tel. +44 1223 336500; Fax. +44 1223 336827.  
Aiwu Zhou: Hongqiao International Institute of Medicine, Shanghai Jiao-Tong University School of 
Medicine, China; aiwu.zhou@googlemail.com; Tel. +86 21 63846590-776909; Fax +86 21 64154900. 
Keywords: renin angiotensin system, serpin, crystal structure, conformational change, site-directed 
mutagenesis, kinetics, angiotensinogen, proteolysis, aspartic protease, hypertension
Abstract 
The renin-angiotensin cascade is a hormone 
system that regulates blood pressure and fluid 
balance. Renin-mediated cleavage of the 
angiotensin I peptide from the N-terminus of 
angiotensinogen (AGT1) is the rate-limiting step 
of this cascade; however, the detailed molecular 
mechanism underlying this step is unclear. Here, 
we solved the crystal structures of glycosylated 
                                                   
1Abbreviations: ACE: angiotensin converting enzyme; 
AGT: angiotensinogen; CBG: corticosteroid-binding 
globulin; mPEG: methoxypolyethylene glycol; PEI: 
polyethylenimine; PMSF: phenylmethylsulfonyl 
fluoride; PNGase F: peptide-N-glycosidase F; RCL: 
human AGT (2.30 Å resolution), its encounter 
complex with renin (2.55 Å), AGT cleaved in its 
reactive center loop (RCL; 2.97 Å) and spent AGT 
from which the N-terminal angiotensin peptide 
was removed (2.63 Å). These structures revealed 
that AGT undergoes profound conformational 
changes and binds renin through a tail-into-mouth 
allosteric mechanism that inserts the N-terminus 
into a pocket equivalent to a hormone binding site 
on other serpins. These changes fully extended the 
reactive center loop; rmsd: root-mean-square deviation; 
S-to-R: stressed-to-relaxed; TBG: thyroxine-binding 
globulin; TCEP: tris (2-carboxyethyl) phosphine. 
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N-terminal tail, with the scissile bond for 
angiotensin release docked in renin’s active site. 
Insertion of the N-terminus into this pocket 
accompanied a complete unwinding of helix H of 
AGT, which, in turn, formed key interactions with 
renin in the complementary binding interface. 
Mutagenesis and kinetic analyses confirmed that 
renin-mediated production of angiotensin I is 
controlled by interactions of amino acid residues 
and glycan components outside renin’s active site 
cleft. Our findings indicate that AGT adapts 
unique serpin features for hormone delivery and 
binds renin through concerted movements in the 
N-terminal tail and in its main body to modulate 
angiotensin release. These insights provide a 
structural basis for the development of agents that 
attenuate angiotensin release by targeting AGT’s 
hormone binding pocket.  
Introduction 
Human blood pressure is mainly controlled by 
the renin-angiotensin system, which consists of 
several key components including renin, 
angiotensinogen (AGT), angiotensin converting 
enzyme (ACE) and angiotensin receptors(1). 
Renin is a highly-specific aspartic protease that 
cleaves AGT between Leu10 and Val11 to release 
the N-terminal angiotensin I peptide(1) . This 
peptide is subsequently processed by ACE to form 
angiotensin II, which is the major biologically 
active hormone and functions through binding to 
its receptors. Cleavage of AGT by renin is the rate-
limiting step of the renin-angiotensin system(2) . 
This step is tightly regulated in mammals to 
maintain normal blood pressure, with subtle 
changes often associated with hypertension and 
other cardiovascular diseases. For example, a mild 
increase (10-20%) in plasma concentrations of 
human AGT caused by the Met235Thr 
polymorphism is often associated with essential 
hypertension(3),(4). Also, an AGT mutation where 
Leu10 is replaced by a Phe, resulting in a mere 2-
fold increase in the cleavage efficiency of the 
mutant by renin, is associated with the 
development of preeclampsia, a life-threatening 
hypertensive disorder during pregnancy(5). 
Previous structural and biochemical studies of 
renin-AGT interactions have revealed that renin 
specifically recognizes and cleaves the N-terminal 
tetradecapeptide of AGT, the only known natural 
substrate of renin. It has also been shown that the 
body of the AGT molecule is critical for efficient 
angiotensin I release by renin, as the KM value for 
AGT is 10-fold lower than that of a synthetic 14-
residue peptide derived from the AGT N-
terminus(6, 7). Our previous structural 
characterizations of AGT and renin have shown 
that AGT adopts the typical serpin (serine protease 
inhibitor) framework with a central beta-sheet and 
a surface-exposed reactive loop, and that binding 
of AGT by renin induces substantial movements 
of both a surface loop and the N-terminal tail, 
linked by a labile disulfide bond(8). However due 
to limited resolution (4.35 Å) of the AGT/renin 
complex structure, the detailed molecular 
interactions between AGT and renin remain 
obscure. Furthermore, human plasma AGT is a 
heterogeneous glycoprotein resulting from its 
variable glycosylation. One of the glycosylation 
sites at Asn14 is close to the scissile bond (Leu10-
Val11) and has been shown to affect the efficiency 
of angiotensin I release(9, 10). It is unclear how 
the presence of carbohydrate at the glycosylation 
sites would affect the conformation and activity of 
AGT. 
To address these questions, here we have 
solved high-resolution crystal structures of human 
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glycosylated AGT, its encounter complex with 
renin, AGT cleaved in the reactive center loop, and 
the spent AGT from which the N-terminal 
angiotensin peptide has been removed by renin. 
These structures together with detailed 
biochemical characterizations revealed that, when 
renin binds AGT, the N-terminal angiotensin tail 
is inserted into a pocket on AGT that is a hormone-
binding site in other serpins. This and other 
binding interactions induce profound 
conformational changes in AGT. 
Results 
Crystal structures of human glycosylated AGT, 
its complex with renin, loop-cleaved AGT and 
spent AGT 
In order to understand how renin binds AGT 
and how glycosylation affects their interaction, 
here we have prepared glycosylated human AGT 
variants (Asn137/271/295Gln, Cys232/308Ser, 
termed AGT-N14) where only a single 
glycosylation site on Asn14 is retained. 
Subsequently we prepared spent AGT where the 
N-terminal 10-residue angiotensin I peptide was 
removed from the AGT-N14 expression construct 
and AGT-N14 cleaved between Gln412 and 
Leu413 by thermolysin treatment. An inactive 
human renin variant (Asp226Ala) was also 
prepared from HEK293 cells for crystallizing the 
encounter complex of renin and AGT. The 
structures of AGT, its complex with renin, the 
spent AGT and RCL-cleaved AGT were solved at 
2.3 Å, 2.55 Å, 2.6 Å, and 2.97 Å resolution 
respectively. All structures were refined to good 
geometry with statistics shown in Table 1.  
The N-terminal tail is sequestered in native 
AGT 
The crystal structure of AGT-N14 shows that 
AGT retains a typical serpin fold with the extra 63-
residue extension at the N-terminus being well 
ordered, similar to the previous unglycosylated 
AGT structures(8). The conserved disulfide bond 
between Cys18 and Cys138 is properly formed 
and the N-terminal tail residues form extensive 
hydrophobic interactions and several hydrogen 
bonds with the body of AGT (Figure 1A, B). 
Residues Ile5, Phe8, Leu10, Val11 and Ile12 pack 
with residues (Leu66, Met72, Leu76 and Phe79) 
from helix A and residues (Val131, Trp133 Val142, 
Val147) from the CD loop (loop connecting 
helices C and D) and helix D. This leads to the 
scissile bond of Leu10-Val11 being buried in an 
inaccessible position (Figure 1C). The potential 
drawback of this configuration is that AGT has to 
undergo conformational changes for the scissile 
bond to move out to bind renin, while the 
advantage is that it could protect the scissile bond 
from non-specific cleavage by other proteases.  
The binding interactions between renin and 
AGT 
The crystal structure of the AGT-renin 
complex shows that the N-terminal tail of AGT is 
docked in the substrate-binding pocket of renin 
(Figure 2). The total surface area buried in the 
interface between AGT and renin is more than 
2100 Å2: interactions between the N-terminal 
peptide and the renin active site account for about 
50% of the buried surface while interactions 
between the bodies of AGT and renin account for 
the rest. Renin is an aspartic protease in which the 
active site is formed by the junction of two similar 
domains, each containing an aspartic acid residue 
(Asp38 and Asp226 in human renin) to form a 
catalytic dyad that hydrolyzes the peptide 
bond(11). Although the Asp226 of renin was 
mutated to alanine to obtain a stable initiation 
complex, the binding interactions within the renin 
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active site largely resemble those seen in the 
crystal structure of a renin-peptide complex solved 
previously (PDB 1SMR)(12). The Asp38 of renin 
is hydrogen bonded to the carbonyl oxygen of the 
scissile bond and to a water molecule that is also 
within hydrogen bond distance to the other 
mutated aspartic acid (Figure 3A). Therefore, the 
active site conformation in our structure is 
consistent with the well-accepted proposal(13) 
that Asp38 protonates the carbonyl oxygen of the 
scissile bond of the natural protein substrate, while 
the Asp226 carboxyl is ionized and deprotonates 
the catalytic water molecule that initially bridges 
the two aspartates. One of the imidazole nitrogens 
(NE2) of His9 is hydrogen-bonded to the Oγ of 
Ser233, whereas the other nitrogen (ND1) 
connects His13 through a bridging water (Figure 
3B). Neither His9 nor His13 are connected to the 
catalytic dyad directly or indirectly. Therefore, it 
is unlikely that the peak at the slightly acidic pH 
6.5 in the pH activity profile for the cleavage of 
AGT by human renin is solely determined by the 
histidines around the scissile bond(12, 14, 15). 
The hydrogen bond network Trp45-Tyr83-water-
Ser41-Asp38 is also present, connecting the N-
flap of renin with the catalytic site (Figure 3A). 
Such a network is conserved in aspartic proteases 
and has been shown to be essential for renin 
activity(16). However there are subtle difference 
in the renin conformations between the complexes. 
The N-flap of renin in the renin-AGT complex is 
in a relatively open conformation with the tip of 
the flap shifted by about 5 Å when compared to 
that seen in the renin-peptide complex (Figure 3D). 
This is likely induced by the longer N-terminal tail 
of AGT, which holds renin against the body of 
AGT. In addition to the essential hydrogen bonds 
around the active site, hydrophobic interactions 
account for the complementary steric fitting of the 
peptide in the renin binding pocket. There are four 
main subsites: S3, S1, S1’ and S2’ (according to 
the nomenclature of Schechter and Berger(17)), 
accommodating Phe8, Leu10, Val11 and Ile12 of 
the peptide (Figure 3C). It has been suggested that 
the sizes and shapes of these binding pockets 
partly determine the species specificity of the 
action of renin on AGT(12). 
The substantial interactions between the 
bodies of the two molecules are mainly 
hydrophobic (Figure 4A, B). The surface of AGT 
involved in binding renin includes residues from 
helix H, helix A, helix C, the CD-loop and the IJ-
loop (loop connecting helices I and J). Helix A of 
AGT lies across the binding interface with side 
chains of six hydrophobic residues (Leu68, Ala71, 
Met72, Met75, Leu76 and Phe79) facing towards 
renin and stacking with Ala116, Leu117, Met120, 
Leu121, Leu252 and Phe253 of renin (Figure 4B). 
Residues in helix C (Ala127 and Ile128) and in the 
IJ-loop (Leu368, Pro369 and Ile371) also form 
hydrophobic interactions with renin residues 
Leu54 and Tyr55. There are also several hydrogen 
bonds between the bodies of the two molecules 
(Figure 4C). Arg83 of AGT forms a cluster of 
hydrogen bonds with renin residues (Arg53, 
Leu54, Thr56). Asn331 and Asn334 in the 
unwound helix H form hydrogen bonds with 
Tyr60 and Tyr15 of renin, respectively. Arg53 in 
renin forms a salt bridge with Glu367 and a cluster 
of hydrogen bonds with the main chain of the IJ-
loop in AGT.  
It has been well documented that human renin 
cannot efficiently process AGT from mouse and 
rat(18–20). A sequence alignment shows that, of 
the interacting residues, Arg83, Asn331 and 
Asn334 are not strictly conserved among species. 
To assess the importance of these residues in AGT, 
we prepared AGT mutants in which Arg83, 
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Asn331 and Asn334 were replaced with the 
corresponding residues from rat, mouse and sheep 
AGT and assessed their binding affinity and 
catalytic efficiency towards human renin (Figure 
4D, Table 2 and Figure S-1). The Asn334Thr 
mutation did not significantly affect either the 
binding affinity or the catalytic efficiency. The 
catalytic efficiency for cleavage of AGT Arg83His 
was about half that of the wild type, and the 
binding affinity was 2.2-fold lower. Most 
significantly, the binding affinity of the 
Asn331Asp variant decreased about 4.6-fold with 
the consequence of a 5-fold decrease in the 
catalytic release of angiotensin I. This indicates 
that residues involved in the body-to-body 
interface between AGT and renin play a key role 
in determining the catalytic efficiency and binding 
affinity of renin. This explains the species 
specificity of human renin towards AGT from 
other mammals and also explains why intact AGT 
has a 10-fold lower KM value compared to the 
tetradecapeptide derived from its N-terminus(6, 7).  
To further characterize the binding 
interactions between the bodies of AGT and renin, 
we prepared spent AGT where the angiotensin 
peptide is removed by renin, measured its binding 
affinity towards renin and tested its effect on renin 
cleavage of intact AGT. One might expect spent 
AGT to have modest binding affinity towards 
renin as the binding interface between the bodies 
of two molecules covers more than 1000Å2 buried 
surface, however we found spent glycosylated 
AGT cannot form a stable complex with renin 
when analyzed by gel filtration or native PAGE 
(data not shown). The binding affinity derived 
from steady state analysis gives a KD value of 
13μM (Figure S-2) which is 640-fold weaker than 
the binding of intact AGT to renin. We then tested 
if spent AGT could interfere with the interaction 
between renin and intact AGT through a product 
inhibition effect. As shown in Figure S-3, renin 
readily cleaves an AGT fusion protein to generate 
spent AGT. When increasing amounts of spent 
AGT were added, substantial inhibition arose at a 
concentration of 0.65µM spent AGT (Figure S-3, 
lane 5), which is about half the concentration of 
intact AGT in the assay (1.1µM). As a negative 
control, the addition of another serpin, protein Z-
dependent inhibitor, had no effect on renin 
cleavage of AGT. The concentration of circulating 
intact AGT in plasma of normotensive subjects is 
about 1.1µM and the spent AGT appears to be far 
lower(21, 22). Even though the relative abundance 
of spent AGT versus intact AGT increases in 
plasma in some pathologic states when renin 
secretion is stimulated(21), it is still highly 
unlikely that the spent AGT concentration could 
be on the same level as the intact AGT. Therefore, 
we conclude that spent AGT does have a product 
inhibition effect on renin cleavage of intact AGT; 
however, it is unlikely to be significant in vivo. It 
appears that the optimal binding affinity between 
the bodies of AGT and renin has been selected to 
enhance the activity of renin and at the same time 
to avoid significant product inhibition under 
physiological conditions. The lack of ordered 
structure for residues 16-28 near the N-terminus or 
for residues 132-141 in the CD-loop in bound 
AGT may be relevant; if these residues were well-
ordered, they would be positioned to interact with 
the N-flap of renin, which could increase binding 
affinity beyond the optimal range. 
Conformational changes of human AGT 
induced by renin binding 
Comparison of structures of native AGT and 
its complex with renin shows that the N-terminal 
tail of AGT undergoes significant conformational 
changes to dock into the substrate binding site of 
Specificity of angiotensinogen cleavage by renin 
 6 
renin with the scissile bond presented 
appropriately for hydrolysis by the two active 
aspartate residues (Figure 5A, B). In native AGT, 
the region of the N-terminal tail near the scissile 
bond Leu10-Val11 forms hydrophobic interactions 
with helix A residues such as Leu68, Met72, 
Leu76 and Phe79 (Figure 1C). These interactions 
are lost on binding to renin, when the scissile bond 
shifts about 19 Å from its sequestered position to 
an extended configuration (Figures 5A and 5B), 
but are replaced by new interactions with renin 
residues such as Leu117, Leu121, Leu252 and 
Phe253 (Figure 4B). Complex formation is also 
associated with secondary structural changes in 
other areas of AGT. Notably, helix A is extended 
by nearly 2 turns and bent towards the core of AGT, 
with the side chain of Trp92 at the C-terminal part 
of helix A flipping out to allow space (Figure 5C). 
Minor conformational changes around helices I 
and J are also likely induced by renin binding.  
Most unexpectedly, we have found that the N-
terminus of AGT emerges from the renin active 
cleft and pokes into a surface cavity surrounded by 
helix H, sheet B and helix A of AGT (Figures 6A 
and 6B). This cavity corresponds to the hormone 
binding pocket seen in two other serpins, 
thyroxine-binding globulin (TBG; Figure 6C) and 
cortisol-binding globulin (CBG)(23). The side 
chain of Arg2 of the N-terminus is completely 
buried in the relatively shallow pocket and is 
stabilized by hydrogen bonds with neighboring 
residue Gln300 (Figure 6A). The side chain of 
Val3 interacts with hydrophobic residues within 
this hormone binding pocket, including Met336. 
The entire helix H (residues 330-336) is unwound, 
with the shift of residues 333-337 opening up the 
pocket to accommodate the N-terminal tail and 
with Asn331 and Asn334 shifting to form key 
hydrogen bonds with the body of renin (Figure 4C 
and 5C, Table 2). At the same time, helix G is 
extended by a half turn. AGT appears to have 
adopted a “tail-in-mouth” mechanism for 
interacting with renin, where insertion of its N-
terminus into the hormone binding pocket helps to 
stabilize a new conformation that forms a 
complementary surface on AGT for renin binding. 
It is tempting to speculate that any ligands that 
bind tightly to this pocket in intact AGT would 
attenuate the interaction between AGT and renin 
and have an anti-hypertensive effect.  
To further dissect the conformational 
plasticity of AGT, we then solved the crystal 
structure of spent AGT and compared it with that 
of intact AGT. The spent AGT retains a similar 
fold to native AGT with an rmsd of 0.63 Å over 
355 Cα atoms (Figure 5D). Helices A, I and J of 
spent AGT, which are involved in renin binding, 
have the same conformation as in native AGT. 
Hence, it is possible that the native and spent AGT 
have similar angiotensin I independent functions 
through hypothetical receptors to the same serpin 
characteristic binding sites(24, 25). In contrast, 
there are significant movements in the CD-loop. 
To some extent this may reflect flexibility in this 
part of the molecule, influenced by different 
crystal packing environments: the CD-loop is 
involved in packing interactions in the crystals of 
both intact and spent AGT. However, it is notable 
that the rearrangement of the CD-loop in spent 
AGT places the side chain of Trp133 in the 
hydrophobic pocket occupied by the scissile 
peptide region in intact AGT, replacing the side 
chain of Val11. Finally, helix H in the spent human 
AGT is disordered with no clear electron density 
while it is in a helical conformation in intact AGT. 
This may also be influenced by crystal packing; if 
helix H in spent AGT were ordered in the same 
conformation as in intact AGT, it would clash with 
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the CD-loop of a neighboring molecule. The 
lability of helix H in human AGT is reminiscent of 
the rat and mouse AGT structures (PDB 2WXX, 
2WXY, 2WXZ, 2WY0 and 2WY1), in all of which 
helix H exists in an unwound or slightly distorted 
conformation. It is plausible that helix H of AGT 
is inherently unstable and can equilibrate between 
both conformations, only forming favorable 
interactions with renin when induced by the 
insertion of the N-terminus of AGT in the 
hormone binding pocket. A reduced stability of 
helix H in spent AGT could partly explain why 
spent AGT only has a relatively low binding 
affinity towards renin (Figure S-2).  
To confirm conclusions from biochemical 
experiments that cleavage of the reactive center 
loop of AGT does not trigger the S to R transition 
characteristic of inhibitory serpins, we solved the 
structure of AGT cleaved by thermolysin 
treatment and compared it with that of intact AGT. 
Loop cleavage indeed induces no significant 
conformational changes, with an rmsd of only 0.28 
Å over 371 Ca atoms (Figure S-4). The cleaved 
loop is disordered but is not inserted into the 
central b-sheet A. 
Glycosylation effect on AGT 
It has been demonstrated that glycosylation of 
human AGT is not crucial for its intracellular 
trafficking and secretion, but it does play an 
important role in affecting the interactions 
between AGT and renin with altered enzyme 
kinetic parameters(9). Notably, unglycosylated 
AGT is a better substrate than glycosylated AGT 
for renin cleavage, and the carbohydrate at 
glycosylation site Asn14 seems to play a key role 
in affecting renin activity(5, 22) It is further 
confirmed here that both the quadruple 
glycosylation mutant N14/137/271/295Q, termed 
N4, where all four glycosylation sites were 
mutated, and the AGT N14Q variant can be 
processed by renin about 2.5-fold faster than the 
fully glycosylated wild type AGT (Table 2). Here 
in our crystal structures, glycans linked to 
glycosylation site Asn14 could be resolved with 
clear electron density (Figures S-5). In the native 
AGT structure, the oligosaccharide attached to 
Asn14 forms several stabilizing hydrogen bonds 
to the surrounding residues of AGT (Lys146, 
Ser16 and Thr17) (Figure S-5A), while in the 
complex structure, the carbohydrates make no 
direct contacts with neighboring renin residues 
(Figure S-5B). As the Cα atom of Asn14 shifts 
about 16 Å upon complex formation, it is likely 
that shifting the bulky carbohydrates linked to 
Asn14 and breaking their hydrogen bonds during 
renin binding contribute to the lower efficiency of 
renin in processing glycosylated AGT. Thus this 
glycosylation at Asn14 probably also contributes 
to the well-known observation that human AGT 
can only be efficiently cleaved by primate renin 
but not by renins from non-primates that lack 
Asn14 in their copies of AGT(9, 10, 26). 
Discussion 
The serpin superfamily is classically 
characterized by proteins that fold into a 
conserved metastable tertiary structure that has the 
ability to undergo profound conformational 
changes for protease inhibition. However, three 
members of this superfamily, TBG, CBG and AGT, 
have lost the ability to inhibit proteases and 
become hormone carriers instead. TBG and CBG 
are close homologues, with thyroxine and cortisol 
binding to equivalent pockets on the serpin 
framework, formed by helices H and A and strands 
3-5 of the B-sheet(23, 27, 28). Thyroxine and 
cortisol release are triggered by a conformational 
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S-to-R (stressed-to-relaxed) transition similar to 
that seen in inhibitory serpins. In contrast, it has 
been shown that AGT has lost the ability to 
undergo this typical serpin S-to-R transition(29), 
confirmed here by our structure of loop-cleaved 
AGT, so it was very puzzling why the serpin 
framework was selected in the course of evolution 
as an angiotensin carrier. Does the serpin structure 
of AGT merely provide a carrier for the added-on 
tail? One part of the answer may be that AGT was 
originally a bifunctional protein serving both as a 
protease inhibitor and the donor of a peptide 
hormone, which still seems to be the case in the 
lamprey(30–32). 
Here we have addressed this puzzle by solving 
the structures of glycosylated AGT and its 
complex with renin. This reveals for the first time 
the extensive hydrophobic interactions and 
hydrogen bonds in the renin active site and in the 
interface between the two components. Renin 
binding of AGT requires substantial 
conformational changes in the N-terminal tail of 
AGT, in which the scissile peptide of angiotensin 
is expelled from a sequestered position to dock 
into the active site pocket of renin. This mode of 
renin binding is likely achieved through 
competition between the N-terminal tail of AGT 
and the body of renin for binding to helix A of 
AGT. Most remarkably we found that the N-
terminus of AGT inserts into the equivalent of the 
hormone-binding pocket seen in TBG and CBG. 
This insertion is accompanied by the unwinding of 
helix H, which we know from structures of rat and 
mouse AGT to be inherently unstable; this 
unwinding allows residues such as Asn331 and 
Asn334 to form critical interactions with renin. 
The conformational change shifts the Cα atom of 
Asn331 by more than 6 Å during complex 
formation. Substituting this residue with the 
corresponding Asp331 seen in mouse or rat AGT 
results in a 5-fold decrease in catalytic efficiency 
of renin cleavage (Table 2), consistent with the 
finding that human renin cleaves mouse and rat 
AGT with significantly lower catalytic efficiency 
than human substrate. Thus, renin binding of AGT 
induces concerted movements in angiotensin 
including expulsion of the N-terminal tail from a 
sequestered position, docking into the renin active 
site, insertion of the N-terminus into the hormone 
binding pocket, unwinding of helix H and 
subsequent extension of helix G, all of which 
ultimately leads to a complementary binding 
interface between the bodies of AGT and renin. 
Altogether this further supports the idea that AGT 
is not just a passive carrier of an angiotensin 
peptide and that sophisticated use is made of its 
serpin framework, especially its “hormone 
binding” pocket, in the efficient release of 
angiotensin by renin cleavage.  
The serpin framework, like many other protein 
scaffolds, is also subject to post-translational 
modifications such as oxidation or glycosylation, 
and these modifications can have significant 
effects on activity or conformation. For example, 
the activity of SerpinB9, a regulator of the 
cytotoxic lymphocyte granzyme B, is reversibly 
inhibited by vicinal disulfide bond formation in 
the reactive loop(33). In our previous study, we 
revealed that AGT has a conserved, labile 
disulfide bond between Cys18 and Cys138 and 
that oxidized AGT is a better substrate than the 
reduced form for renin cleavage. Most intriguingly 
it was found that an increased ratio of oxidized 
AGT over the reduced form in plasma is 
associated with preeclampsia, a hypertensive 
disease during pregnancy(8). This finding has now 
been confirmed by an independent large case-
control study in patients with preeclampsia using 
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an improved ELISA method(34).  
Serpin activity can also be modulated by 
glycosylation. For example, the carbohydrate 
linked to Asn135 in antithrombin can affect 
heparin binding, with fully glycosylated 
antithrombin (the alpha form) having lower 
affinity(35). Glycans linked to Asn347 in the 
reactive center loop of CBG also retard proteolysis 
and subsequent cortisol release(36). Similarly, the 
presence in AGT of glycans linked to Asn14 
decrease angiotensin I release by renin cleavage. 
We speculate that the heterogeneity of 
glycosylation at this site could serve as an 
additional control point to modulate angiotensin I 
release, in the same way that variable 
glycosylation affects the rate of activation of 
plasminogen by tissue-type plasminogen 
activator(37).  
As the human renin-angiotensin system differs 
significantly from those of other species(38) and 
many residues in the renin-AGT interface are not 
conserved, we have looked for polymorphisms of 
these residues. A recent analysis of exome 
sequences in over 60,000 individuals, carried out 
by the Exome Aggregation Consortium(39) 
allows polymorphisms to be detected at much 
lower frequency in the human population than 
previously possible. The database reveals that 
some mutations in residues that interact in the 
complex between AGT and renin do occur at low 
frequency. In AGT, an Arg83His substitution is 
seen twice in 121400 sequence reads (a frequency 
of 1.65x10-5); we have shown that this substitution 
would reduce catalytic efficiency by a factor of 2 
(Figure S-1, Table 2). An Arg83Cys substitution 
occurs at the same frequency, and Arg83Leu at a 
frequency of only one in 121400 (8.24x10-6). 
Polymorphisms are also found for two of the renin 
residues that contact Arg83 in AGT (Figure 4C, 
Table 2). The substitution Arg53His is seen at a 
frequency of 3.88x10-5 and Arg53Cys at a 
frequency of 1.4x10-5. Perhaps the most 
interesting polymorphism is a Cys18Arg 
substitution in AGT, which occurs at a frequency 
of 1.95x10-3, a level at which about one in 250 
individuals should be heterozygous. It seems 
likely that the Cys18Arg variant would behave in 
the same way as reduced wild-type AGT, resulting 
in a lowered response to the effects of oxidative 
stress(8) and a somewhat reduced response to 
triggers of the RAS. It would be intriguing to learn 
whether individuals carrying at least one copy of 
this polymorphism have reduced risks of 
cardiovascular complications, such as 
hypertension or preeclampsia, or whether it is 
disadvantageous under any circumstances. 
Overall our findings indicate that, over the 
course of evolution, AGT has retained many 
features found in other serpins, adapting them to 
modulate angiotensin release by renin cleavage. 
AGT binds renin through a concerted tail-in-
mouth movement using a site that binds hormones 
in other serpins; this contributes to the unwinding 
of helix H of AGT when forming key interactions 
with renin in the complementary binding interface. 
This new understanding of the interaction of renin 
and AGT provides the basis for the development 
of new agents to attenuate angiotensin release 
through targeting the binding interface or the 
“hormone binding” pocket of AGT.  
Experimental procedures 
Recombinant protein expression 
The encoding genes for full-length human 
AGT and prorenin including signal peptide were 
amplified from I.M.A.G.E clones (Source 
BioScience, #4213559 for human AGT and 
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#5188566 for human prorenin) and inserted into 
the pCEP4 vector (Invitrogen). The coding 
sequence of spent AGT was inserted into a 
modified pCEP4 vector with the antitrypsin signal 
peptide at its N-terminus for secretion. All the 
constructs included a 6*His tag at the C-terminus 
of the gene and were verified by DNA sequencing 
(Source BioScience) before being transfected 
transiently into HEK293 EBNA cells using 
polyethylenimine (PEI, linear, MW 25000, 
Polysciences, Inc.). Recombinant proteins were 
purified from concentrated serum-free expression 
medium by nickel affinity (HisTrap, GE 
Healthcare Life Sciences) and anion exchange 
chromatography (Hitrap Q, GE Healthcare Life 
Sciences) consecutively.  
Mutations in the crystallized AGT-N14 protein 
Three out of four potentially glycosylated 
asparagines in human AGT were mutated to 
glutamines to minimize the glycosylation 
heterogeneity of AGT for crystallization. Two free 
cysteines (Cys232 and Cys308) were replaced 
with serines to avoid potential aggregation.  
The actual mutations in AGT-N14 were 
Asn137/271/295Gln and Cys232/308Ser. The 
same mutations were introduced to spent AGT-
N14 for crystallization. A cysteine modification 
experiment confirmed that Cys18-Cys138 
disulfide bond is properly formed within these 
variants (Figure S-6). All the mutations were 
introduced by site-directed mutagenesis using the 
QuickChange kit (Agilent Technologies). All the 
primers for molecular cloning and mutagenesis are 
listed in Supporting Information Table S-1. 
Preparation of reactive center loop-cleaved 
AGT 
The reactive center loop (RCL) cleaved 
human AGT was made by thermolysin cleavage 
between Gln412-Leu413 of AGT-N14 and 
confirmed by SDS-PAGE (Figure S-7) and mass 
spectrometry. The ratio of protein/protease ratio 
and reaction time were optimized by incubating 
AGT-N14 (singly glycosylated at Asn14) with a 2-
fold serial dilution of thermolysin for various 
times. The final digestion condition for large scale 
prep combined 1mg/ml full-length AGT and 
thermolysin with a protein/protease ratio of 
3200:1 (W/W) at room temperature for 3h in a 
buffer containing 10mM Tris, 0.15M NaCl and 
10mM CaCl2. The reaction was stopped by 
addition of 10mM EDTA and further purified by 
ion exchange chromatography before 
crystallization.  
Preparation of AGT-renin complex 
The Asp226Ala mutant of human prorenin, 
with one of the two active site aspartate residues 
mutated to Ala, was incubated with trypsin (Sigma) 
at an optimized 200:1 molar ratio to remove the 
prosegment, and then the reaction was stopped by 
adding 1mM phenylmethylsulfonyl fluoride 
(PMSF). After removal of PMSF and buffer 
exchange to 10mM Tris pH 7.4 and 0.15 M NaCl, 
the resulting inactive renin Asp226Ala was 
deglycosylated with peptide-N-glycosidase F 
(PNGase F) (NEB), at an optimized ratio of 1U 
PNGase F to 1µg renin. The deglycosylated renin 
Asp226Ala was further purified by binding to a 
nickel column to remove PNGaseF. The stable 
AGT:renin complex was made by mixing AGT-
N14 and inactive renin Asp226Ala mutant at a 
1:1.2 molar ratio and purified by size-exclusion 
chromatography using a HiLoad 16/60 Superdex 
200 (GE Healthcare Life Sciences) column 
equilibrated with 10mM Tris pH7.4 and 0.1M 
NaCl. Fractions containing the complex were 
collected and concentrated to 8mg/ml for 
crystallization. 
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Crystallization, data collection and structure 
determination 
The diffraction quality crystals of intact,  
spent and RCL-cleaved AGT were grown by 
microseeding in 96-well sitting drop plates (300nl 
reservoir, 200nl 10mg/ml protein and 100nl seeds) 
against 80μl of a range of concentrations of 
(NH4)2SO4 and different pH buffers. The seeds 
were prepared using unglycosylated AGT crystals 
grown in 20% PEG6000, 1.0M LiCl and 0.1M Tris 
pH8.0. As frequently observed in previous 
examples of cross-seeding with non-identical 
proteins(40), the resulting crystals did not share 
the same crystal packing. A similar method was 
applied to grow crystals of the complex. 
Optimized complex crystals were obtained by 
equilibrating 1μl of 8mg/ml protein, 1.5μl of 
reservoir and 0.5μl seeds in sitting drop plates 
against 1ml of reservoir solution of 1.74M 
(NH4)2SO4 and 0.1M Tris pH7.6. The intact and 
spent AGT crystals, grown in 96-well sitting drop 
plates, were cryo-protected by adding 0.5μl 
perfluoropolyether oil (Hampton research) to the 
top of the drops. The complex crystals were 
soaked in cryo-solutions of 2M Li2SO4, 1M 
(NH4)2SO4 plus 0.1M Tris pH7.6 before 
harvesting. All the crystals covered with cryo-
solutions were flash-cooled in liquid nitrogen.  
Diffraction data were collected at beamlines 
I04 (spent AGT), I04-1 (intact AGT, AGT:renin 
complex) and I02 (RCL-cleaved AGT) of the 
Diamond Synchrotron Light Source and processed 
with Mosflm(41) and Aimless(42) in the CCP4 
program suite. Resolution was decided by 
CC1/2>0.5 and <I/s> over 1 in the outer resolution 
shell(43, 44). The structures of intact, loop-
cleaved and spent AGT were solved by molecular 
replacement in Phaser(45) by searching with the 
unglycosylated AGT structure (PDB 2WXW). 
The crystals of intact and loop-cleaved AGT each 
contained one copy in the asymmetric unit, while 
the spent AGT crystal contained two copies. The 
complex structure was solved by molecular 
replacement using the unglycosylated AGT 
structure (PDB 2WXW), from which the N-
terminal residues 1-30 had been trimmed, and 
renin (PDB 2BKS) as search models. One copy of 
the complex was present in the asymmetric unit. 
Manual model building was carried out in 
COOT(46) and further refinement was performed 
in Phenix.refine(47) and Refmac(48). The final 
models were validated using MolProbity(49) and 
final refinement statistics for all four structures are 
shown in Table 1. The carbohydrate structures 
were built with consideration of the correct core 
carbohydrate linkages(50). Torsion angles for 
carbohydrate linkages were validated using the 
program carp(51). Molecular graphics were 
prepared using Pymol(52) and protein:protein 
interactions were analyzed using PDBePISA(53).  
Enzyme kinetics of the human renin and AGT 
reaction 
For steady-state kinetics, the reaction time and 
renin concentration were optimized to ensure 
product formation is linear with time and the renin 
concentration is well below the KM of the 
system. Briefly, various concentrations of AGT 
mutants (eight 2-fold dilutions up to around 10* 
KM) were incubated with 0.2nM renin at 37°C for 
1h in a buffer of 10mM Tris pH7.4, 0.15M NaCl 
and 0.25mg/ml bovine serum albumin. The 
reactions were stopped by heating the sample at 
98˚C for 5min. The amount of released Ang I 
peptide was quantified by immunoassay (S-1188 
kit, Peninsula Laboratories, LLC) and plotted 
against the substrate concentrations. The key 
consideration was that the measured Ang I 
concentrations must be within the linear range of 
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the standard curve. The kinetic parameters (Vmax 
and KM) for the cleavage of AGT by renin were fit 
with the standard Michaelis-Menten equation 
using GraphPad Prism 5, and kcat was calculated as 
Vmax/[E]t. The mean and standard deviation 
calculated from 3 independent experiments are 
presented in Table 2.  
The affinity of human AGT binding to renin 
The binding kinetics for the interaction 
between AGT and inactivated renin were 
measured using a FortéBio Octet Red96 biolayer 
interferometry system (Menlo Park, CA, U.S.). 
Renin Asp226Ala was biotinylated preferentially 
on N-terminal α-amino groups at pH 6.2 using EZ-
link-NHS-PEG4-Biotin (Thermo Scientific). Such 
preferential labelling is achieved by using a 
reaction pH that is lower than the typical range 
used for reaction by NHS-ester reagents(54). The 
optimized biotinylation condition was a 1:0.8 ratio 
of protein to reagent at 4°C for two hours. Non-
reacted NHS-PEG4-Biotin was removed by a 
Zeba spin desalting column (7K MWCO, Thermo 
Scientific). 2.5µg/ml biotinylated renin 
Asp226Ala mutant was loaded on to streptavidin 
biosensors (18-5019, FortéBio). A range of 2-fold 
dilutions of AGT mutants was prepared in 10mM 
Tris pH7.4, 0.15M NaCl and 1% BSA covering 
10*KD to 0.1*KD. Responses were processed with 
the FortéBio Data Analysis 7.0 software. The 
kinetic association rate constant (kon) and 
dissociation rate constant (koff) were generated 
using a 1:1 binding model by a global fit without 
linked Rmax. The equilibrium dissociation constant 
(KD) was calculated as koff divided by kon. For the 
reaction of renin and spent AGT, as the on and off 
rates were very fast and all the association binding 
curves reached equilibrium, a steady state analysis 
was performed to calculate KD. Three independent 
assays were performed to calculate the mean and 
standard deviation (Table 2).  
Alkylation of free sulfhydryl groups of 
cysteines in AGT 
5µl of 1mg/ml protein was reduced by 5µl of 
10mM tris (2-carboxyethyl) phosphine (TCEP) at 
room temperature for 20min. Then 10µl of 20mM 
methoxypolyethylene glycol (mean molecular 
weight of 2,000)-maleimide (mPEG2000-mal; 
Sunbright ME-020MA, NOF Europe) was added 
to alkylate the free sulfhydryl groups of cysteines. 
The mixture was incubated at room temperature 
for 40min. An aliquot of each sample was also 
incubated with mPEG2000-mal without reduction 
by TCEP. Samples were separated by SDS-PAGE 
and stained with InstantBlue (Expedeon) to 
observe the band shift after modification. The 
reduced disulfide bond reacts with two 
mPEG2000-mal moieties, causing a 4kD shift in 
SDS-PAGE. Note that the two free Cys232 and 
Cys308 of wild-type AGT were mutated to serine 
in this experiment. 
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Table	1.	Data	collection	and	refinement	statistics. 
*corresponding to UniProt entry P01019 for AGT and P00797 for renin. 
**Values in parentheses are for highest-resolution shell. 
†100th percentile is the best among structures of comparable resolutions. 0th percentile is the worst.  
 
Intact human AGT AGT-Renin 
complex 
Spent AGT RCL-cleaved AGT 




    
Synchrotron stations DLS I04-1 DLS I04-1 DLS I04 DLS I02 
Space group P41 P6322 P2 P41 
a,b,c; Å 71.35, 71.35, 125.3 124.1, 124.1, 260.9 86.3, 41.04, 129.95 80.14, 80.14, 117.13 
α, β, γ; ⁰ 90, 90, 90 90, 90, 120 90, 107.82, 90 90, 90, 90 








Rmerge** 0.057 (0.702) 0.209 (1.251) 0.139 (0.801) 0.214 (1.282) 
<I/σ(I)>** 16.6 (2.3) 10.2 (2.1) 6.9 (1.3) 6.5 (1.4) 
CC1/2** 0.999 (0.511) 0.998 (0.674) 0.987 (0.534) 0.987 (0.530) 
Completeness, %** 99.9 (99.9) 100 (100) 99.3 (99.3) 100 (100) 
Redundancy** 6.5 (5.4) 12.7 (12.9) 3.3 (3.3) 6.7 (7.1) 
Refinement 
    
Rwork/Rfree 0.178/0.196 0.208/0.234 0.241/0.284 0.219/0.237 
No. of unique reflections** 27786 (2704) 39584 (4393) 26230 (1930) 14563 (1106) 
No. of atoms (non H) 3328 6136 5923 3336 
Average B-factors 63.5 40.4 42.5 68.7 
RMS deviations 
    
Bond lengths Å 0.003 0.002 0.003 0.003 
Bond angles,⁰ 0.613 1.192 0.707 0.754 
Ramachandran favored region, % 96.8 97.6 97.7 96.4 
Ramachandran outliers, % 0 0 0 0 
MolProbity score† 1.54 (99%) 0.85(100%) 1.28 (100%) 1.27 (100%) 
PDB code 5M3Y 6I3F 5M3X 6I3I 




Bio-layer interferometry was used to measure the binding kinetic constants (kon, koff and KD) between the 
inactivated human renin mutant (D226A) and human AGT in both wild-type and mutant forms (as indicated 
on the left column; N4 represents the quadruple glycosylation mutant N14/137/271/295Q). The enzymatic 
kinetic parameters (KM, kcat and kcat/KM) for the cleavage efficiency by wild-type human renin of human 
AGT mutants (the same panel of AGT mutants as the binding assay) were measured by quantifying the 
released Ang I. All the proteins were expressed in HEK293EBNA cells. The mean and standard deviation 














Wild-type 2.15 (±0.36) 
× 104 
4.37 (±1.2) × 
10-4 
20.3±2.2 (100%) 0.20±0.01 0.76±0.08 0.25±0.01 
(100%) 




91.5±5.3 (456%) 0.14±0.01 2.56±0.37 0.05±0.01 (21%) 






0.20±0.03 1.42±0.12 0.14±0.01 (54%) 




27.9±3.7 (138%) 0.16±0.01 0.76±0.05 0.22±0.01 (84%) 




1.2±0.2 (5.9%) 0.44±0.02 0.67±0.10 0.65±0.08 
(255%) 




5.8±1.1 (28.9%) 0.35±0.01 0.56±0.02 0.64±0.03 
(252%) 
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Figure	1.	The	crystal	structure	of	human	glycosylated	AGT.	(A)	The	N-terminal	tail	sequence	of	AGT,	indicating	the	renin	and	ACE	cleavage	sites,	the	glycosylation	site	and	the	conserved	disulfide	bond.	(B)	The	structure	of	AGT	is	shown	as	a	cartoon.	The	serpin	template	is	in	grey	and	helix	A	(hA)	is	in	marine	with	the	A-sheet	(sA)	in	light	blue	and	the	disordered	reactive	center	loop	(RCL)	in	red	dashes.	The	Ang	I	segment	is	in	magenta	and	the	following	amino-tail	 is	 in	green	with	the	scissile	bond	shown	as	magenta	and	green	spheres.	Cysteine	18	in	the	amino	tail	forms	a	disulfide	bond	with	Cysteine	138	of	 the	CD-loop	(brown).	The	glycan	attached	to	Asn14	is	shown	as	green	sticks.	The	segment	 from	Glu20-Pro29	 (dashed,	 pale	 green)	 is	 disordered	 in	 the	 structure	 and	modelled	 for	illustration.	Helix	H	(hH)	is	in	red	and	helix	G	(hG)	is	in	wheat	color.	(C)	Surface	representation	of	the	main	body	of	AGT,	with	 the	 extra	N-terminus	 (1-63)	 shown	 in	 cartoon	 representation.	The	Ang	 I	peptide	is	mainly	stabilized	by	hydrophobic	interactions	with	the	main	body.	Residues	I5,	F8,	L10,	V11	and	I12	(shown	as	sticks)	form	hydrophobic	interactions	with	residues	in	the	CD-loop	(V131,	P132	and	W133	as	brown	surface),	helix	A	(L68,	M72,	L76	and	F79	as	marine	surface)	and	helix	D	(hD,	L142	and	V147	as	cyan	surface).	The	scissile	bond	(L10-V11)	is	buried	in	the	hydrophobic	cavity.		 	
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Figure	3.	Interactions	inside	the	renin	active	cleft.	(A)	Renin	residues	are	shown	as	grey	and	the	AGT	peptide	is	in	magenta.	D38	in	renin	is	hydrogen-bonded	to	the	carbonyl	oxygen	of	the	scissile	bond	and	a	water	(W1)	that	is	also	within	hydrogen-bond	range	to	the	other	mutated	aspartic	acid	(A226).	The	conserved	hydrogen	bond	network	W45-Y83-water	(W2)-S41-D38	is	present.	(B)	H9	in	AGT	is	hydrogen-bonded	to	S233.	H9	also	connects	to	H13	through	a	bridging	water	(W3).	S84	in	the	N-flap	forms	a	hydrogen	bond	with	a	water	(W4),	which	connects	to	the	carbonyl	oxygen	of	H9.	(C)	Binding	subsites	 in	 the	renin	active	cleft.	Subsite	S3	(P118,	F119,	L121,	A122	and	F124	of	renin)	accommodates	F8;	S1	(F119,	F124,	V127,	V36	and	Y83)	accommodates	L10;	S1’	 (L224	and	 I305)	accommodates	V11;	and	S2’	(I137,	L81	and	Y83)	accommodates	I12.	The	N-flap	of	renin	is	shown	as	yellow	and	the	C-flap	is	in	purple.	(D)	The	N-flap	of	renin	(yellow)	in	the	AGT-renin	complex	adopts	an	 ‘open’	position	with	a	movement	of	4.8	Å	compared	 to	 its	conformation	 in	 the	unbound	renin	(cyan,	 PDB	 1BBS).	 There	 is	 no	 such	 conformational	 change	 when	 a	 decapeptide	 substrate	(corresponding	to	residues	4-14	of	rat	AGT)	is	bound	to	mouse	submaxillary	renin	(pink,	PDB	entry	1SMR).	The	N-terminal	residues	1-10	of	the	AGT	peptide	are	in	magenta	and	the	following	residues	11-15	and	the	glycan	are	shown	as	green.	 		 	




Figure	4.	Interactions	between	renin	and	angiotensinogen	in	the	complex.	(A)	An	opened-up	cartoon	view	of	the	interface	(with	the	renin	moiety	rotated	180°	around	the	y	axis)	illustrating	the	hydrophobic	 interactions	 and	 hydrogen-bonded	 residues	 (sticks).	 (B)	 An	 opened-up	 surface	representation	highlights	hydrophobic	interactions	at	the	interface.	(C)	Cartoon	view	of	the	interface,	with	hydrogen	bonds	shown	as	red	dashes	between	interacting	residues	(sticks).	Renin,	on	the	left,	is	shown	as	grey	with	interacting	residues	in	yellow.	AGT,	on	the	right,	is	shown	using	the	colors	defined	for	 Figures	 1.	 (D)	 Residues	 involved	 in	 hydrogen-bonding	 interactions	 are	 listed,	 along	 with	 the	identities	 of	 corresponding	 residues	 in	 AGT	 from	 other	 species.	 The	 plot	 shows	 that	 cleavage	efficiency	is	reduced	when	N331	or	R83	of	human	AGT	are	replaced	by	equivalent	residues	from	rat	or	mouse	AGT	respectively.	The	detailed	kinetic	constants	are	listed	in	Table	2.		 	
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Figure	5.	Conformational	changes	of	angiotensinogen	upon	renin	interaction.	Side	views	of	AGT	alone	(A)	and	from	the	complex	with	renin	(B)	illustrate	the	substantial	movement	of	the	N-terminus	of	AGT	 into	 the	 renin	active	 cleft.	The	 scissile	bond	 (shown	as	 spheres)	moves	18.6	Å	during	 the	complex	formation.	The	color	coding	and	abbreviations	are	the	same	as	in	Figure	1.	(C)	Superposed	structures	 of	 native	 AGT	 and	 AGT	 from	 the	 complex	 with	 renin	 show	 significant	 structural	rearrangement	of	helices	H,	A,	I,	and	J	(hH,	hA,	hI,	and	hJ)	of	AGT	upon	renin	binding.	Native	AGT	is	shown	as	grey	with	a	cyan	helix	H	and	AGT	in	the	complex	is	color	coded	as	AGT	in	Figure	1.	Helix	H	is	completely	unwound	with	the	Cα	atom	of	N331	(shown	as	cyan	stick	in	native	AGT	and	red	stick	in	AGT	complexed	with	renin)	shifting	more	than	6Å	to	interact	with	Y60	of	renin.	Helix	A	is	extended	by	two	turns	with	the	side	chain	of	W92	(shown	as	magenta	stick	in	native	AGT	and	marine	stick	in	AGT	complexed	with	renin)	at	the	tip	of	helix	A	being	flipped	out.	(D)	Superposed	structures	of	native	(grey)	and	spent	AGT	(same	color	coding	as	AGT	in	Figure	1)	show	that	spent	AGT	largely	resembles	native	AGT,	but	with	differences	in	helix	H	and	the	CD-loop	(blue	in	spent	AGT).	Helix	H	of	spent	AGT	
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is	completely	disordered		 	
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Figure	6.	The	insertion	of	the	N-terminal	peptide	into	the	hormone	binding	pocket.	(A)	Renin	binding	 results	 in	 the	N-terminus	of	AGT	being	 inserted	 into	 the	hormone	binding	pocket	 and	 in	unwinding	of	helix	H.	The	side	chain	of	Arg2	is	largely	buried	and	forms	stabilizing	interactions	with	Gln300.	Val3	and	Tyr4	also	form	hydrophobic	interactions	with	surrounding	residues.	(B)	There	is	clear	electron	density	for	all	the	residues	in	the	N-terminus	(grey	mesh,	2mFo-DFc	map,	contoured	at	1.0	sigma,	including	density	within	1.6	Å	of	atoms	in	the	N-terminus).	(C).	A	similarly	located	pocket	is	used	to	bind	thyroxine	(T4,	spheres)	in	thyroxine	binding	globulin	(TBG).	 	
